Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating Expenses:
Research and development	$ 3,004	$ 1,701	$ 8,030	$ 6,086
General and administrative	2,068	2,062	6,980	7,105
Total operating expenses	5,072	3,763	15,010	13,191
Operating loss	(5,072)	(3,763)	(15,010)	(13,191)
Other income (expense):
Investment income, net	175	214	611	585
Interest expense	0	0	0	(5)
Total other income (expense), net	175	214	611	580
Net loss	(4,897)	(3,549)	(14,399)	(12,611)
Less - net income (loss) attributable to noncontrolling interests	1	1	6	(2)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (4,898)	$ (3,550)	$ (14,405)	$ (12,609)
Basic and diluted loss per share
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ (0.47)	$ (0.36)	$ (1.40)	$ (1.31)
Weighted average common shares outstanding
Basic and diluted shares	10,411	9,745	10,279	9,634